| An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer CM Cosgrove, DL Tritchler, DE Cohn, DG Mutch, CM Rush, HA Lankes, ... Gynecologic oncology 148 (1), 174-180, 2018 | 104 | 2018 |
| Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival CM Cosgrove, DE Cohn, H Hampel, WL Frankel, D Jones, JP McElroy, ... Gynecologic oncology 146 (3), 588-595, 2017 | 101 | 2017 |
| Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study KK Leslie, VL Filiaci, AR Mallen, KW Thiel, EJ Devor, K Moxley, ... Gynecologic oncology 161 (1), 113-121, 2021 | 48 | 2021 |
| Mismatch repair deficiency identifies patients with high‐intermediate–risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker FJ Backes, J Haag, CM Cosgrove, A Suarez, DE Cohn, PJ Goodfellow Cancer 125 (3), 398-405, 2019 | 47 | 2019 |
| Ovarian effects of radiation and cytotoxic chemotherapy damage CM Cosgrove, R Salani Best Practice & Research Clinical Obstetrics & Gynaecology 55, 37-48, 2019 | 40 | 2019 |
| Phase III MIRASOL (GOG 3045/ENGOT-Ov55) study: mirvetuximab soravtansine vs. investigator’s choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian … KN Moore, A Angelergues, GE Konecny, S Banerjee, S Pignata, ... J Clin Oncol 41, abstrLBA5507, 2023 | 38 | 2023 |
| TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG … KW Thiel, EJ Devor, VL Filiaci, D Mutch, K Moxley, A Alvarez Secord, ... Journal of clinical oncology 40 (28), 3289-3300, 2022 | 30 | 2022 |
| Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients H Hampel, R Pearlman, A de la Chapelle, CC Pritchard, W Zhao, D Jones, ... Gynecologic oncology 160 (1), 161-168, 2021 | 30 | 2021 |
| A rare case of NUT midline carcinoma A Ball, A Bromley, S Glaze, CA French, P Ghatage, M Köbel Gynecologic oncology case reports 3, 1-3, 2013 | 29 | 2013 |
| Up-front multigene panel testing for cancer susceptibility in patients with newly diagnosed endometrial cancer: a multicenter prospective study MD Levine, R Pearlman, H Hampel, C Cosgrove, D Cohn, A Chassen, ... JCO precision oncology 5, 1588-1602, 2021 | 23 | 2021 |
| Where you live matters: a National Cancer Database study of Medicaid expansion and endometrial cancer outcomes DA Barrington, JA Sinnott, C Calo, DE Cohn, CM Cosgrove, AS Felix Gynecologic oncology 158 (2), 407-414, 2020 | 19 | 2020 |
| Endometrial cancer: molecular classification and future treatments B Corr, C Cosgrove, D Spinosa, S Guntupalli BMJ medicine 1 (1), 2022 | 18 | 2022 |
| The prognostic significance of aortic lymph node metastasis in endometrial cancer: potential implications for selective aortic lymph node assessment CM Cosgrove, DE Cohn, J Rhoades, AS Felix Gynecologic oncology 153 (3), 505-510, 2019 | 18 | 2019 |
| Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer KN Moore, A Angelergues, GE Konecny, Y García, S Banerjee, D Lorusso, ... New England Journal of Medicine 389 (23), 2162-2174, 2023 | 16 | 2023 |
| Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab J Gillen, KA Mills, J Dvorak, B Zheng, T Thai, R Salani, CM Cosgrove, ... Gynecologic oncology reports 30, 100502, 2019 | 13 | 2019 |
| MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization CJ Walker, CM Rush, P Dama, MJ O’Hern, CM Cosgrove, JL Gillespie, ... JNCI: Journal of the National Cancer Institute 110 (5), 517-526, 2018 | 12 | 2018 |
| The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG … IS Hagemann, W Deng, RJ Zaino, MA Powell, C Gunderson, C Cosgrove, ... Gynecologic oncology 160 (3), 660-668, 2021 | 10 | 2021 |
| Primum non nocere: Are we ready for POLE testing in endometrial cancer? CM Cosgrove, DE Cohn, PJ Goodfellow Gynecologic oncology 147 (2), 240-242, 2017 | 10 | 2017 |
| TP53 mutation and abnormal p53 expression in endometrial cancer: associations with race and outcomes K Whelan, M Dillon, KC Strickland, B Pothuri, V Bae-Jump, LE Borden, ... Gynecologic oncology 178, 44-53, 2023 | 9 | 2023 |
| Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer FJ Backes, L Wei, M Chen, K Hill, K Dzwigalski, M Poi, M Phelps, R Salani, ... Gynecologic Oncology 162 (3), 619-625, 2021 | 9 | 2021 |
